Xenon Pharmaceuticals (XENE) Profit After Tax (2013 - 2026)
Xenon Pharmaceuticals (XENE) posted quarterly Profit After Tax of -$102.3 million for Q1 2026, down 57.27% year-over-year from -$239.4 million in Q1 2025, and up 4.7% quarter-over-quarter from -$107.4 million in Q4 2025.
Xenon Pharmaceuticals (XENE) Profit After Tax (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has reported Profit After Tax for 14 consecutive years, with -$102.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax fell 57.27% year-over-year to -$102.3 million; the TTM figure through Mar 2026 stood at -$385.3 million (down 52.36% YoY), while the FY2025 annual figure was -$345.9 million, down 47.62% from the prior year.
- Profit After Tax improved to -$102.3 million in Q1 2026 per XENE's latest filing, from -$107.4 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$19.7 million in Q1 2022 and bottomed at -$107.4 million in Q4 2025.
- Historically, Profit After Tax has averaged -$58.6 million across 5 years, with a median of -$48.1 million in 2023.
- Annual changes were most pronounced in 2022 — Profit After Tax sank 153.25% — and 2024, when it decreased 14.87%.
- Xenon Pharmaceuticals' Profit After Tax stood at -$37.4 million in 2022, then declined by 19.78% to -$44.8 million in 2023, then sank by 49.81% to -$67.1 million in 2024, then tumbled by 59.99% to -$107.4 million in 2025, then climbed by 4.7% to -$102.3 million in 2026.
- Business Quant data shows XENE's Profit After Tax at -$102.3 million in Q1 2026, -$107.4 million in Q4 2025, and -$90.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Xenon Pharmaceuticals | 6.03 Bn | 6.03 Bn | - | -112.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -112.18 Mn |
| Mar 31, 2026 | -102.30 Mn |
| Dec 31, 2025 | -107.35 Mn |
| Sep 30, 2025 | -90.90 Mn |
| Jun 30, 2025 | -84.71 Mn |
| Mar 31, 2025 | -65.05 Mn |
| Dec 31, 2024 | -67.10 Mn |
| Sep 30, 2024 | -62.79 Mn |
| Jun 30, 2024 | -57.92 Mn |
| Mar 31, 2024 | -47.93 Mn |
| Dec 31, 2023 | -44.79 Mn |
| Sep 30, 2023 | -48.12 Mn |
| Jun 30, 2023 | -47.46 Mn |
| Mar 31, 2023 | -41.73 Mn |
| Dec 31, 2022 | -37.40 Mn |
| Sep 30, 2022 | -39.12 Mn |
| Jun 30, 2022 | -31.16 Mn |
| Mar 31, 2022 | -19.67 Mn |
| Dec 31, 2021 | -25.56 Mn |
| Sep 30, 2021 | -15.45 Mn |